trending Market Intelligence /marketintelligence/en/news-insights/trending/CAwEpPELVi6dtIoQ46oukA2 content esgSubNav
In This List

Bluebird, apceth Biopharma sign EU commercial production deal for 2 drugs

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Bluebird, apceth Biopharma sign EU commercial production deal for 2 drugs

Bluebird bio Inc. signed a multiyear strategic manufacturing agreement with apceth Biopharma GmbH for the future European commercial production of bluebird's product candidates Lenti-D and LentiGlobin.

Lenti-D is for cerebral adrenoleukodystrophy, a genetic disorder that affects nerve cells in the brain, and LentiGlobin is for transfusion-dependent beta-thalassemia, an inherited blood disease that can cause severe anemia.

Apceth Biopharma will perform clinical manufacturing, process validation activities and commercial manufacturing for both drugs.

Apceth Biopharma is a biopharmaceutical company with a pipeline of cell-based gene therapeutics for the treatment of major chronic diseases and solid cancer.